Novavax to Report First-Quarter Earnings: Is a Beat in Store?

Core Viewpoint - Novavax (NVAX) is expected to exceed earnings expectations in its upcoming first-quarter 2025 report, with a consensus estimate for sales at $71.84 million and earnings at 19 cents per share, following a previous earnings beat of 32% [1]. Group 1: Upcoming Earnings and Sales - The company is anticipated to report earnings on May 8, 2025, before the market opens [1]. - The Zacks Consensus Estimate for sales is $71.84 million, while earnings are estimated at 19 cents per share [1]. Group 2: COVID-19 Vaccine Developments - Sanofi has acquired exclusive global marketing rights for Novavax's protein-based COVID-19 vaccine, which means Novavax is not expected to record product sales from this vaccine [1]. - An update on the technology transfer related to the COVID-19 vaccine to Sanofi and the transfer of marketing authorizations in the U.S. and Europe is expected, with Novavax eligible for milestone payments from Sanofi upon completion [2]. Group 3: Clinical Trials and Pipeline - Novavax has initiated a phase III study for its experimental COVID-19-influenza combination (CIC) and standalone influenza vaccine candidates, comparing their immunogenicity and safety [3]. - The company is also progressing in its preclinical pipeline, which includes vaccines for RSV and H5N1 bird flu, and is exploring new opportunities in diseases like varicella-zoster virus and Clostridium difficile colitis [4]. Group 4: Earnings Surprise History - Novavax has a mixed earnings surprise history, beating estimates in two of the last four quarters and missing in the other two, with an average negative surprise of 0.48% [5]. - Year-to-date, Novavax's shares have declined by 20%, contrasting with a 3% decline in the industry [5]. Group 5: Earnings Prediction Model - The company currently has an Earnings ESP of +495.75% and a Zacks Rank of 3, indicating a good chance of delivering an earnings beat [7].